A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.

A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Carcinoma, Squamous Cell
Combined Modality Therapy
Disease Progression
Disease-Free Survival
Female
Fluorouracil
Head and Neck Neoplasms
Humans
Hydroxyurea
Male
Middle Aged
Neoplasm Staging
Radiotherapy Dosage

authors with profiles

Elizabeth Blair
Kerstin M. Stenson
Daniel J. Haraf
Everett E. Vokes
Ezra Cohen